Can You Cut Lisinopril 40 Mg in Half
This information is intended for employ by health professionals
Lisinopril 5 mg Tablets
Each tablet contains lisinopril dihydrate equivalent to 5 mg anhydrous lisinopril.
For the full list of excipients, run into section six.1
Tablets.
5 mg tablets are white, round biconvex tablets with embossing "v" on one side and breakline on the other side.
The tablets can be divided into equal halves.
Hypertension
Treatment of hypertension.
Heart Failure
Treatment of symptomatic centre failure.
Acute Myocardial Infarction
Short-term (6 weeks) treatment of haemodynamically stable patients inside 24 hours of an acute myocardial infarction.
Renal Complications of Diabetes Mellitus
Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy (see section 5.1).
Lisinopril tin can be used alone or in combination with other antihypertensive agents (meet sections 4.3, 4.4, 4.5 and 5.1).
Lisinopril tablets should be administered orally in a single daily dose. As with all other medication taken once daily, Lisinopril tablets should be taken at approximately the aforementioned time each twenty-four hour period. The absorption of Lisinopril tablets is non affected by food.
The dose should exist individualised according to patient profile and blood pressure response (see section 4.4)
Hypertension
Lisinopril tablets may be used as monotherapy or in combination with other classes of antihypertensive therapy (see sections 4.three, four.4, iv.5 and 5.one).
Starting dose
In patients with hypertension the usual recommended starting dose is x mg. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and /or volume depletion, cardiac decompensation, or astringent hypertension) may experience an excessive blood pressure autumn post-obit the initial dose. A starting dose of 2.5-5 mg is recommended in such patients and the initiation of handling should take place under medical supervision. A lower starting dose is required in the presence of renal impairment (meet Table 1 below).
Maintenance dose
The usual constructive maintenance dosage is 20 mg administered in a single daily dose. In general if the desired therapeutic effect cannot be achieved in a period of 2 to four weeks on a certain dose level, the dose can be further increased. The maximum dose used in long-term, controlled clinical trials was 80 mg/24-hour interval.
Diuretic-Treated Patients
Symptomatic hypotension may occur post-obit initiation of therapy with Lisinopril tablets. This is more likely in patients who are being treated currently with diuretics. Circumspection is recommended therefore, since these patients may be book and/or table salt depleted. If possible, the diuretic should be discontinued two to 3 days earlier beginning therapy with Lisinopril tablets. In hypertensive patients in whom the diuretic cannot be discontinued, therapy with Lisinopril tablets should be initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of Lisinopril tablets should be adjusted co-ordinate to blood pressure response. If required, diuretic therapy may exist resumed (see department 4.four and section 4.5).
Dosage Adjustment In Renal Harm
Dosage in patients with renal impairment should be based on creatinine clearance as outlined in Table 1 below.
Table 1 Dosage aligning in renal damage.
| Creatinine Clearance (ml/min) | Starting Dose (mg/day) |
| Less than 10 ml/min (including patients on dialysis) | 2.5 mg* |
| 10-30 ml/min | 2.5-5 mg |
| 31-80 ml/min | v-10 mg |
* Dosage and/or frequency of administration should be adjusted depending on the blood pressure response.
The dosage may be titrated upward until blood force per unit area is controlled or to a maximum of 40 mg daily.
Use in Hypertensive Paediatric Patients aged 6-16 years
The recommended initial dose is 2.5 mg once daily in patients 20 to <50 kg, and five mg one time daily in patients ≥l kg. The dosage should exist individually adjusted to a maximum of twenty mg daily in patients weighing 20 to <50 kg, and 40 mg in patients ≥fifty kg. Doses above 0.61 mg/kg (or in backlog of 40 mg) have not been studied in paediatric patients (see section 5.1).
In children with decreased renal office, a lower starting dose or increased dosing interval should be considered.
Middle Failure
In patients with symptomatic middle failure, Lisinopril tablets should be used as adjunctive therapy to diuretics and, where advisable, digitalis or beta-blockers. Lisinopril tablets may be initiated at a starting dose of 2.five mg once a day, which should be administered nether medical supervision to determine the initial consequence on the blood pressure. The dose of Lisinopril tablets should be increased:
• Past increments of no greater than 10 mg
• At intervals of no less than ii weeks
• To the highest dose tolerated by the patient upwardly to a maximum of 35 mg once daily.
Dose adjustment should be based on the clinical response of individual patients.
Patients at high risk of symptomatic hypotension e.thou. patients with salt depletion with or without hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy with Lisinopril tablets. Renal function and serum potassium should exist monitored (see section 4.4).
Posology in Astute Myocardial Infarction
Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may exist used together with Lisinopril tablets.
Starting dose (first 3 days later on infarction)
Treatment with Lisinopril tablets may exist started within 24 hours of the onset of symptoms. Treatment should non be started if systolic blood pressure is lower than 100 mm Hg. The first dose of Lisinopril tablets is 5 mg given orally, followed past v mg after 24 hours, x mg after 48 hours and then 10 mg once daily. Patients with a low systolic claret pressure level (120 mm Hg or less) when handling is started or during the first 3 days after the infarction should be given a lower dose - 2.5 mg orally (run across section 4.4).
In cases of renal impairment (creatinine clearance <eighty ml/min), the initial Lisinopril tablets dosage should be adapted according to the patient'southward creatinine clearance (run into Tabular array 1).
Maintenance dose
The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure level less than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may exist given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic claret pressure level less than xc mm Hg for more than 1 hour) Lisinopril tablets should be withdrawn.
Treatment should keep for half-dozen weeks and so the patient should be re-evaluated. Patients who develop symptoms of eye failure should continue with Lisinopril tablets (see department iv.2).
Renal Complications of Diabetes Mellitus
In hypertensive patients with type ii diabetes mellitus and incipient nephropathy, the dose is x mg Lisinopril tablets once daily which can exist increased to 20 mg in one case daily, if necessary, to achieve a sitting diastolic claret pressure below 90 mm Hg.
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril tablets dosage should be adjusted according to the patient'southward creatinine clearance (see Tabular array 1).
Paediatric population
There is limited efficacy and rubber experience in hypertensive children >6 years erstwhile, but no experience in other indications (see section 5.one). Lisinopril is not recommended in children in other indications than hypertension.
Lisinopril is non recommended in children below the age of 6, or in children with severe renal damage (GFR <30ml/min/1.73m2) (meet section 5.2).
Elderly
In clinical studies, there was no age-related alter in the efficacy or safety profile of the drug. When avant-garde historic period is associated with decrease in renal function, however, the guidelines set up out in Table 1 should be used to make up one's mind the starting dose of Lisinopril tablets. Thereafter, the dosage should be adjusted according to the claret force per unit area response.
Use in kidney transplant patients
In that location is no experience regarding the administration of Lisinopril tablets in patients with recent kidney transplantation. Treatment with Lisinopril tablets is therefore not recommended.
• Hypersensitivity to Lisinopril tablets, to whatsoever of the excipients listed in section six.1 or whatever other angiotensin converting enzyme (ACE) inhibitor
• History of angioedema associated with previous ACE inhibitor therapy
• Concomitant use of Lisinopril tablets with sacubitril/valsartan therapy. Lisinopril tablets must not be initiated earlier than 36 hours later on the last dose of sacubitril/valsartan (see sections iv.iv and 4.5).
• Hereditary or idiopathic angioedema
• Second and third trimesters of pregnancy (see sections 4.iv and 4.6).
• In combination with aliskiren-containing medicines in patients with diabetes mellitus (blazon I or Two) or with moderate to astringent renal impairment (GFR < 60 ml/min/1.73m2 (see sections 4.5 and 5.1).
Symptomatic Hypotension
Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In hypertensive patients receiving Lisinopril tablets, hypotension is more than likely to occur if the patient has been volume-depleted eastward.g. past diuretic therapy, dietary salt brake, dialysis, diarrhoea or vomiting, or has astringent renin-dependent hypertension (see section iv.5 and section 4.eight). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most probable to occur in those patients with more severe degrees of center failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In patients at increased gamble of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored. Similar considerations utilize to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.
If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can exist given usually without difficulty once the blood pressure has increased later on book expansion.
In some patients with eye failure who take normal or low blood pressure, boosted lowering of systemic blood pressure may occur with Lisinopril tablets. This upshot is anticipated and is not commonly a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or discontinuation of Lisinopril tablets may be necessary.
Hypotension In Acute Myocardial Infarction
Treatment with Lisinopril tablets must not exist initiated in acute myocardial infarction patients who are at risk of further serious haemodynamic deterioration afterward handling with a vasodilator. These are patients with systolic blood pressure of 100 mm Hg or lower or those in cardiogenic shock. During the starting time 3 days following the infarction, the dose should exist reduced if the systolic blood pressure is 120 mm Hg or lower. Maintenance doses should exist reduced to five mg or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension persists (systolic blood force per unit area less than ninety mm Hg for more than than 1 hour) and then Lisinopril tablets should be withdrawn.
Aortic and mitral valve stenosis / hypertrophic cardiomyopathy
Every bit with other ACE inhibitors, Lisinopril tablets should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.
Renal Function Damage
In cases of renal impairment (creatinine clearance <80 ml/min), the initial Lisinopril tablets dosage should be adjusted according to the patient's creatinine clearance (see Table 1 in section 4.two) so equally a function of the patient'due south response to treatment. Routine monitoring of potassium and creatinine is part of normal medical do for these patients.
In patients with middle failure, hypotension following the initiation of therapy with ACE inhibitors may lead to some farther impairment in renal function. Acute renal failure, normally reversible, has been reported in this situation.
In some patients with bilateral renal artery stenosis or with a stenosis of the artery to a lonely kidney, who accept been treated with angiotensin converting enzyme inhibitors, increases in claret urea and serum creatinine, commonly reversible upon discontinuation of therapy, have been seen. This is specially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, handling should be started under close medical supervision with low doses and conscientious dose titration. Since handling with diuretics may exist a contributory factor to the above, they should be discontinued and renal function should be monitored during the get-go weeks of Lisinopril tablets therapy.
Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, commonly minor and transient, particularly when Lisinopril tablets has been given concomitantly with a diuretic. This is more probable to occur in patients with pre-existing renal damage. Dosage reduction and/or discontinuation of the diuretic and/or Lisinopril tablets may exist required.
In astute myocardial infarction, handling with Lisinopril tablets should not be initiated in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 micromol/50 and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during treatment with Lisinopril tablets (serum creatinine concentration exceeding 265 micromol/l or a doubling from the pre-treatment value) and then the doc should consider withdrawal of Lisinopril tablets.
Hypersensitivity/Angioedema
Angioedema of the face, extremities, lips, natural language, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including Lisinopril tablets. This may occur at any time during therapy. In such cases, Lisinopril tablets should be discontinued promptly and appropriate treatment and monitoring should be instituted to ensure consummate resolution of symptoms prior to dismissing the patients. Even in those instances where swelling of just the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may non be sufficient.
Very rarely, fatalities take been reported due to angioedema associated with laryngeal oedema or natural language oedema. Patients with involvement of the tongue, glottis or larynx, are likely to experience airway obstruction, specially those with a history of airway surgery. In such cases emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patient's airway. The patient should be nether close medical supervision until complete and sustained resolution of symptoms has occurred.
Angiotensin converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-blackness patients.
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (meet four.3).
Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated due to the increased risk of angioedema. Treatment with sacubitril/valsartan must not be initiated earlier than 36 hours later on the last dose of Lisinopril. Handling with Lisinopril must not be initiated earlier than 36 hours after the concluding dose of sacubitril/valsartan (see sections four.3 and 4.5).
Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (due east.g. sirolimus, everolimus, temsirolimus) and vildagliptin may pb to an increased risk of angioedema (e.thou. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.v). Caution should exist used when starting racecadotril, mTOR inhibitors (east.thousand. sirolimus, everolimus, temsirolimus) and vildagliptin in a patient already taking an ACE inhibitor.
Anaphylactoid reactions in Haemodialysis Patients
Anaphylactoid reactions accept been reported in patients dialysed with high flux membranes (e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a unlike type of dialysis membrane or different form of antihypertensive agent.
Anaphylactoid reactions during depression-density lipoproteins (LDL) apheresis
Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.
Desensitisation
Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have sustained anaphylactoid reactions. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld just they take reappeared upon inadvertent re-administration of the medicinal production.
Hepatic failure
Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant necrosis and (sometimes) decease. The mechanism of this syndrome is not understood. Patients receiving Lisinopril tablets who develop jaundice or marked elevations of hepatic enzymes should discontinue Lisinopril tablets and receive advisable medical follow-upward.
Neutropenia/ Agranulocytosis
Neutropenia/ Agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible afterwards discontinuation of the ACE inhibitor. Lisinopril tablets should be used with farthermost caution in patients with collagen vascular illness, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing dumb renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If Lisinopril tablets are used in such patients, periodic monitoring of white claret jail cell counts is advised and patients should exist instructed to report whatever sign of infection.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS)
There is evidence that the concomitant employ of ACE-inhibitors, angiotensin 2 receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including astute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore non recommended (see sections iv.5 and v.1).
If dual occludent therapy is considered admittedly necessary, this should only occur nether specialist supervision and subject to frequent close monitoring of renal office, electrolytes and claret pressure.
ACE-inhibitors and angiotensin 2 receptor blockers should not exist used concomitantly in patients with diabetic nephropathy."
Race
ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.
As with other ACE inhibitors, Lisinopril tablets may be less effective in lowering blood pressure in black patients than in non-blacks, perchance because of a higher prevalence of low-renin states in the black hypertensive population.
Cough
Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced coughing should be considered as part of the differential diagnosis of coughing.
Surgery/Anaesthesia
In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Lisinopril tablets may block angiotensin Two germination secondary to compensatory renin release. If hypotension occurs and is considered to exist due to this mechanism, it tin be corrected past volume expansion.
Hyperkalaemia
Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including Lisinopril tablets. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics (due east.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes, or those patients taking other drugs associated with increases in serum potassium (e.chiliad. heparin, the combination trimethoprim/sulfamethoxazole also known every bit cotrimoxazole). If concomitant use of the above-mentioned agents is accounted advisable, regular monitoring of serum potassium is recommended (run across section four.five).
Diabetic patients
In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the beginning calendar month of handling with an ACE inhibitor (see section four.5 Interaction with other medicinal products and other forms of interaction).
Lithium
The combination of lithium and Lisinopril tablets is generally not recommended (see department four.v).
Pregnancy
ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which accept an established safety profile for employ in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should exist started (meet sections iv.3 and iv.6).
Antihypertensive agents
When Lisinopril tablets is combined with other antihypertensive agents (e.g. glyceryl trinitrate and other nitrates, or other vasodilators), additive falls in claret force per unit area may occur.
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined utilize of ACE-inhibitors, angiotensin 2 receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal office (including acute renal failure) compared to the use of a unmarried RAAS-acting agent (see sections four.3, iv.four and 5.1).
Drugs that may increase the gamble of angioedema
Concomitant treatment of ACE inhibitors with mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus, sirolimus, everolimus) or neutral endopeptidase (NEP) inhibitors (e.g. racecadotril) or tissue plasminogen activator may increase the risk of angioedema.
Diuretics
When a diuretic is added to the therapy of a patient receiving Lisinopril tablets the antihypertensive effect is usually additive.
Patients already on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of claret pressure when Lisinopril tablets is added. The possibility of symptomatic hypotension with Lisinopril tablets tin can be minimised by discontinuing the diuretic prior to initiation of treatment with Lisinopril tablets (meet section 4.2 and section four.4).
Potassium supplements, potassium-sparing diuretics or potassium-containing common salt substitutes and other drugs that may increase serum potassium levels
Although in clinical trials, serum potassium ordinarily remained within normal limits, hyperkalaemia did occur in some patients. The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes and other drugs that may increase serum potassium levels, especially in patients with dumb renal role, may lead to a significant increase in serum potassium.
Monitoring of potassium should be undertaken every bit appropriate. Run across section 4.four. If Lisinopril is given with a potassium losing diuretic, diuretic induced hypokalaemia may be ameliorated.
Ciclosporin
Hyperkalaemia may occur during concomitant utilize of ACE inhibitors with ciclosporin.
Monitoring of serum potassium is recommended.
Heparin
Hyperkalaemia may occur during concomitant use of ACE inhibitors with heparin. Monitoring of serum potassium is recommended.
Lithium
Reversible increases in serum lithium concentrations and toxicity take been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increment the risk of lithium toxicity and enhance the already increased lithium toxicity with ACE inhibitors. Use of Lisinopril tablets with lithium is not recommended, merely if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see department 4.4).
Non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid ≥3g/day
When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acrid at anti-inflammatory dosage regimens, COX-two inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased chance of worsening of renal function, including possible astute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal role. These effects are ordinarily reversible. The combination should be administered with caution, specially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal role after initiation of concomitant therapy, and periodically thereafter.
Gilded
Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can exist very severe) following injectable gilded (for example, sodium aurothiomalate) have been reported more oft in patients receiving ACE inhibitor therapy.
Tricyclic antidepressants / Antipsychotics /Anaesthetics
Concomitant utilise of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may effect in further reduction of blood force per unit area (meet section four.4).
Sympathomimetics
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.
Antidiabetics
Epidemiological studies have suggested that concomitant assistants of ACE inhibitors and antidiabetic medicinal products (insulins, oral hypoglycaemic agents) may crusade an increased claret glucose lowering effect with risk of hypoglycaemia. This miracle appeared to be more likely to occur during the first weeks of combined handling and in patients with renal impairment.
Co-trimoxazole (trimethoprim/sulfamethoxazole)
Patients taking concomitant co-trimoxazole (trimethoprim/sulfamethoxazole) may be at increased run a risk of hyperkalaemia (see section 4.iv).
Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates
Lisinopril tablets may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics, beta-blockers and/or nitrates.
Pregnancy
The use of ACE inhibitors is not recommended during the outset trimester of pregnancy (see section four.iv). The use of ACE inhibitors is contra indicated during the second and 3rd trimester of pregnancy (run across department iv.three and four.iv).
Epidemiological evidence regarding the take a chance of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in adventure cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which accept an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.
Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal part, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (Encounter department v.3.). Should exposure to ACE inhibitor have occurred from the second trimester of pregnancy, ultrasound check of renal office and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (encounter sections iv.3 and 4.four).
Breast-feeding
Because no information is available regarding the use of Lisinopril tablet during breastfeeding, Lisinopril tablet is not recommended and alternative treatments with meliorate established rubber profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
When driving vehicles or operating machines it should exist taken into account that occasionally dizziness or tiredness may occur.
The following undesirable effects accept been observed and reported during treatment with Lisinopril tablets and other ACE inhibitors with the following frequencies: Very mutual (≥1/10), common (≥1/100 to <one/ten), uncommon (≥i/one,000 to <1/100), rare (≥1/x,000 to <1/one,000), very rare (<1/10,000), not known (cannot be estimated from the available information).
| Claret and the lymphatic system disorders: | |
| rare: | decreases in haemoglobin, decreases in haematocrit. |
| very rare: | bone marrow low, anaemia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis (run across section four.4), haemolytic anaemia, lymphadenopathy, autoimmune affliction |
| Allowed system disorders | |
| not known: | anaphylactic/anaphylactoid reaction |
| Endocrine Disorders | |
| rare: | syndrome of inappropriate antidiuretic hormone secretion (SIADH) |
| Metabolism and nutrition disorders | |
| very rare: | hypoglycaemia |
| Nervous system and psychiatric disorders: | |
| common: | dizziness, headache |
| uncommon: | mood alterations, paraesthesia, vertigo, taste disturbance, sleep disturbances, hallucinations. |
| rare: | mental confusion, olfactory disturbance |
| Not known: | depressive symptoms, syncope. |
| Cardiac and vascular disorders: | |
| common: | orthostatic effects (including hypotension) |
| uncommon: | myocardial infarction or cerebrovascular blow, possibly secondary to excessive hypotension in loftier risk patients (see section iv.4), palpitations, tachycardia. Raynaud'due south phenomenon |
| Respiratory, thoracic and mediastinal disorders: | |
| common: | cough |
| uncommon: | rhinitis |
| very rare: | bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia |
| Gastrointestinal disorders: | |
| common: | diarrhoea, vomiting |
| uncommon: | nausea, abdominal pain and indigestion |
| rare: | dry out mouth |
| very rare: | pancreatitis, intestinal angioedema, hepatitis- either hepatocellular or cholestatic, jaundice and hepatic failure (encounter section 4.4) |
| Peel and subcutaneous tissue disorders: | |
| uncommon: | rash, pruritus |
| rare: | hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis, and/or larynx (meet department iv.4), urticaria, alopecia, psoriasis |
| very rare: | sweating, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, cutaneous pseudolymphoma |
| A symptom complex has been reported which may include one or more than of the following: fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), elevated red blood prison cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological manifestations may occur. Renal and urinary disorders: | |
| common: | renal dysfunction |
| rare: | uraemia, acute renal failure |
| very rare: | oliguria/anuria |
| Reproductive system and breast disorders: | |
| uncommon: | impotence |
| rare | gynaecomastia |
| General disorders and assistants site conditions: | |
| uncommon: | fatigue, asthenia |
| Investigations: | |
| uncommon: | increases in blood urea, increases in serum creatinine, increases in liver enzymes, hyperkalaemia |
| rare: | increases in serum bilirubin, hyponatraemia. |
Safety information from clinical studies propose that lisinopril is generally well tolerated in hypertensive paediatric patients, and that the prophylactic profile in this historic period grouping is comparable to that seen in adults.
Reporting of suspected adverse reactions
Reporting suspected agin reactions afterward authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal production. Healthcare professionals are asked to study whatever suspected adverse reactions via: Yellow Card Scheme
Website: www.mhra.gov.great britain/yellowcard or search for MHRA Yellow Card in the Google Play or Apple tree App Store
Limited information are available for overdose in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory stupor, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.
The recommended treatment of overdose is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may as well be considered. If ingestion is recent, take measures aimed at eliminating Lisinopril tablets (e.g., emesis, gastric lavage, administration of absorbents and sodium sulphate). Lisinopril tablets may be removed from the full general circulation by haemodialysis (see section iv.four). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should exist monitored frequently.
Pharmacotherapeutic grouping: Angiotensin converting enzyme inhibitors, ATC lawmaking: C09A A03
Mechanism of Activity
Lisinopril tablets is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin 2. Angiotensin II as well stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. The latter subtract may issue in an increase in serum potassium concentration.
Pharmacodynamic furnishings
Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with depression renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a stiff vasodilatory peptide, play a office in the therapeutic effects of lisinopril remains to be elucidated.
Clinical efficacy and prophylactic
The outcome of Lisinopril tablets on mortality and morbidity in heart failure has been studied by comparing a high dose (32.5 mg or 35 mg in one case daily) with a low dose (two.5 mg or five mg once daily). In a study of 3164 patients, with a median follow up period of 46 months for surviving patients, loftier dose Lisinopril tablets produced a 12% risk reduction in the combined endpoint of all-crusade mortality and all-cause hospitalisation (p = 0.002) and an 8% run a risk reduction in all-cause mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk reductions for all-cause bloodshed (8%; p = 0.128) and cardiovascular mortality (ten%; p = 0.073) were observed. In a post-hoc analysis, the number of hospitalisations for eye failure was reduced by 24% (p=0.002) in patients treated with loftier-dose Lisinopril tablets compared with low dose. Symptomatic benefits were like in patients treated with high and depression doses of Lisinopril tablets.
The results of the written report showed that the overall adverse result profiles for patients treated with high or low dose Lisinopril tablets were similar in both nature and number. Predictable events resulting from ACE inhibition, such as hypotension or altered renal part, were manageable and rarely led to treatment withdrawal. Coughing was less frequent in patients treated with high dose Lisinopril tablets compared with low dose.
In the GISSI-iii trial, which used a 2x2 factorial design to compare the effects of Lisinopril tablets and glyceryl trinitrate given lone or in combination for 6 weeks versus control in nineteen,394, patients who were administered the handling within 24 hours of an acute myocardial infarction, Lisinopril tablets produced a statistically pregnant adventure reduction in mortality of eleven% versus command (2p=0.03). The risk reduction with glyceryl trinitrate was not significant only the combination of Lisinopril tablets and glyceryl trinitrate produced a pregnant risk reduction in bloodshed of 17% versus control (2p=0.02). In the sub-groups of elderly (historic period > 70 years) and females, pre-defined as patients at high take chances of mortality, significant do good was observed for a combined endpoint of mortality and cardiac role. The combined endpoint for all patients, as well every bit the loftier-take a chance sub-groups, at 6 months also showed meaning benefit for those treated with Lisinopril tablets or Lisinopril tablets plus glyceryl trinitrate for 6 weeks, indicating a prevention issue for Lisinopril tablets. As would be expected from whatever vasodilator treatment, increased incidences of hypotension and renal dysfunction were associated with Lisinopril tablets treatment just these were non associated with a proportional increase in mortality.
In a double-blind, randomised, multicentre trial which compared Lisinopril tablets with a calcium channel blocker in 335 hypertensive Blazon 2 diabetes mellitus subjects with incipient nephropathy characterised by microalbuminuria, Lisinopril tablets ten mg to xx mg administered in one case daily for 12 months, reduced systolic/diastolic blood force per unit area by thirteen/10 mmHg and urinary albumin excretion charge per unit by 40%. When compared with the calcium channel blocker, which produced a similar reduction in blood force per unit area, those treated with Lisinopril tablets showed a significantly greater reduction in urinary albumin excretion rate, providing evidence that the ACE inhibitory action of Lisinopril tablets reduced microalbuminuria by a direct mechanism on renal tissues in addition to its claret pressure lowering effect.
Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect on levels of glycated haemoglobin (HbA1c).
Renin-angiotensin organisation (RAS)-acting agents
Ii large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Solitary and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) accept examined the employ of the combination of an ACE-inhibitor with an angiotensin 2 receptor blocker.
ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type ii diabetes mellitus accompanied by evidence of stop-organ impairment. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
These studies accept shown no significant benign consequence on renal and/or cardiovascular outcomes and mortality, while an increased adventure of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.
ACE-inhibitors and angiotensin 2 receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.
Altitude (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Illness Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney affliction, cardiovascular affliction, or both. The study was terminated early because of an increased risk of agin outcomes. Cardiovascular decease and stroke were both numerically more than frequent in the aliskiren group than in the placebo group and adverse events and serious agin events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.
Paediatric population
In a clinical study involving 115 paediatric patients with hypertension, aged vi-16 years, patients who weighed less than l kg received either 0.625 mg, 2.v mg or 20 mg of lisinopril once a solar day, and patients who weighed 50 kg or more received either ane.25 mg, five mg or forty mg of lisinopril once a solar day. At the end of two weeks, lisinopril administered once daily lowered trough blood pressure in a dose-dependent fashion with a consistent antihypertensive efficacy demonstrated at doses greater than i.25 mg.
This outcome was confirmed in a withdrawal stage, where the diastolic pressure rose by about 9 mm Hg more in patients randomized to placebo than it did in patients who were randomized to remain on the center and loftier doses of lisinopril. The dose-dependent antihypertensive effect of lisinopril was consequent beyond several demographic subgroups: age, Tanner stage, gender, and race.
Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.
Absorption
Post-obit oral administration of lisinopril, peak serum concentrations occur within most 7 hours, although in that location was a trend to a small filibuster in time taken to reach peak serum concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25% with inter-patient variability of 6-sixty% over the dose range studied (5-fourscore mg). The absolute bioavailability is reduced approximately xvi% in patients with heart failure. Lisinopril absorption is not affected by the presence of food.
Distribution
Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin converting enzyme (ACE). Studies in rats point that lisinopril crosses the blood-brain bulwark poorly.
Emptying
Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. On multiple dosing lisinopril has an effective one-half-life of aggregating of 12.half-dozen hours. The clearance of lisinopril in salubrious subjects is approximately 50 ml/min. Declining serum concentrations exhibit a prolonged terminal stage, which does not contribute to drug accumulation. This concluding stage probably represents saturable binding to ACE and is not proportional to dose.
Hepatic impairment
Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption (well-nigh xxx% as determined by urinary recovery) but an increment in exposure (approximately fifty%) compared to healthy subjects due to decreased clearance.
Renal impairment
Impaired renal office decreases elimination of lisinopril, which is excreted via the kidneys, but this decrease becomes clinically important but when the glomerular filtration charge per unit is below thirty ml/min. In balmy to moderate renal impairment (creatinine clearance 30-80 ml/min) mean AUC was increased by 13% but, while a 4.5-fold increment in hateful AUC was observed in severe renal impairment (creatinine clearance 5-30 ml/min).
Lisinopril can be removed by dialysis. During iv hours of haemodialysis, plasma lisinopril concentrations decreased on average by threescore%, with a dialysis clearance between 40 and 55 ml/min.
Center failure
Patients with middle failure have a greater exposure of lisinopril when compared to healthy subjects (an increase in AUC on average of 125%), merely based on the urinary recovery of lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.
Paediatric population
The pharmacokinetic profile of lisinopril was studied in 29 paediatric hypertensive patients, aged between 6 and 16 years, with a GFR in a higher place thirty ml/min/1.73m2. After doses of 0.1 to 0.2 mg/kg, steady state elevation plasma concentrations of lisinopril occurred within 6 hours, and the extent of assimilation based on urinary recovery was about 28%. These values are similar to those obtained previously in adults.
AUC and Cmax values in children in this study were consistent with those observed in adults.
Elderly
Elderly have higher blood levels and higher values for the surface area under the plasma concentration time curve (increased approximately 60%) compared with younger subjects.
Preclinical data reveal no special hazard for humans based on conventional studies of full general pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin converting enzyme inhibitors, equally a class, have been shown to induce adverse effects on the belatedly foetal development, resulting in foetal death and congenital effects, in particular affecting the skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have as well been reported. These developmental anomalies are thought to be partly due to a direct activeness of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting from maternal hypotension and decreases in foetal-placental claret flow and oxygen/nutrients delivery to the foetus.
Mannitol
Calcium hydrogen phosphate dihydrate
Maize starch
Starch, pregelatinised
Magnesium stearate
Silica, colloidal anhydrous
Not applicable.
ii years.
Do not store above 30°C.
Carton containing xiv, 28, 30 or 98 tablets in transparent PVC/PVDC/Aluminium blisters.
Non all pack sizes may be marketed.
The easiest mode to break the tablet is illustrated below:
- place the tablet with the score on top
- place thumb and index of the same manus on each side of the score line and press equally shown on the drawing.
Any unused product or waste material material should be disposed of in accord with local requirements
Accord Healthcare Limited
319 Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom
PL 20075/0131
18/09/2008
09/06/2020
Source: https://www.medicines.org.uk/emc/product/6100/smpc
Post a Comment for "Can You Cut Lisinopril 40 Mg in Half"